Title: 
Official Title: To address patent thickets.
Number of Sections: 2
Source: versions - Introduced in House
Media Type: text/xml

================================================================================

Section 1:
1.Short title
 This Act may be cited as the Eliminating Thickets to Increase Competition Act or the ETHIC Act.

Section 2:
2.Addressing patent thickets 
(a)Limit on number of patents per patent group that may be asserted in action for infringementSection 271(e) of title 35, United States Code, is amended by adding at the end the following:  (7) (A)A person who brings an action for infringement of a patent under this section against a party described in subparagraph (B) may assert in the action not more than one patent per Patent Group. 
(B)A party described in this subparagraph is— (i)a person who— 
(I)submits an application for approval of a drug under subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355), or is a holder of such an approved application; or (II)submits an application for licensure of a biological product under section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)), or is a holder of such a licensure; or 
(ii)a person making, using, selling, offering for sale, introducing or delivering into interstate commerce, or importing— (I)a drug approved pursuant to an application under subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355); or 
(II)a biological product licensed under section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)). (C)A person who brings an action described in subparagraph (A) asserting a patent against a party may not bring any additional actions described in that subparagraph asserting a patent in the same Patent Group against that party. 
(D) 
(i)For purposes of this paragraph, the term Patent Group means 2 or more commonly owned patents or applications that— (I)are identified on 1 or more disclaimers under section 253 to another commonly owned patent; or 
(II)are subject to 1 or more disclaimers under section 253 to another commonly owned patent. (ii)For purposes of clause (i)(I)— 
(I)each patent or application that identifies the same patent or application on a disclaimer under section 253 is part of the same Patent Group; and (II)each patent or application that is identified on a disclaimer under section 253 is part of the same Patent Group as the patent or application subject to the disclaimer.. 
(b)ApplicabilityThe amendment made by subsection (a) shall apply with respect to an application submitted under subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)) on or after the date of enactment of this Act.


================================================================================

Raw Text:
119 HR 3269 IH: Eliminating Thickets to Increase Competition Act
U.S. House of Representatives
2025-05-08
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.



I119th CONGRESS1st SessionH. R. 3269IN THE HOUSE OF REPRESENTATIVESMay 8, 2025Mr. Arrington (for himself, Mr. Doggett, Mr. Issa, Ms. Jayapal, and Mr. Pfluger) introduced the following bill; which was referred to the Committee on the JudiciaryA BILLTo address patent thickets. 
1.Short title
 This Act may be cited as the Eliminating Thickets to Increase Competition Act or the ETHIC Act.
2.Addressing patent thickets 
(a)Limit on number of patents per patent group that may be asserted in action for infringementSection 271(e) of title 35, United States Code, is amended by adding at the end the following:  (7) (A)A person who brings an action for infringement of a patent under this section against a party described in subparagraph (B) may assert in the action not more than one patent per Patent Group. 
(B)A party described in this subparagraph is— (i)a person who— 
(I)submits an application for approval of a drug under subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355), or is a holder of such an approved application; or (II)submits an application for licensure of a biological product under section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)), or is a holder of such a licensure; or 
(ii)a person making, using, selling, offering for sale, introducing or delivering into interstate commerce, or importing— (I)a drug approved pursuant to an application under subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355); or 
(II)a biological product licensed under section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)). (C)A person who brings an action described in subparagraph (A) asserting a patent against a party may not bring any additional actions described in that subparagraph asserting a patent in the same Patent Group against that party. 
(D) 
(i)For purposes of this paragraph, the term Patent Group means 2 or more commonly owned patents or applications that— (I)are identified on 1 or more disclaimers under section 253 to another commonly owned patent; or 
(II)are subject to 1 or more disclaimers under section 253 to another commonly owned patent. (ii)For purposes of clause (i)(I)— 
(I)each patent or application that identifies the same patent or application on a disclaimer under section 253 is part of the same Patent Group; and (II)each patent or application that is identified on a disclaimer under section 253 is part of the same Patent Group as the patent or application subject to the disclaimer.. 
(b)ApplicabilityThe amendment made by subsection (a) shall apply with respect to an application submitted under subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)) on or after the date of enactment of this Act.